Hemming Johansson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hemming Johansson has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Mia Bergenmar
Department of Oncology-Pathology, Karolinska Institutet, Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden
5 shared publications - Yvonne Brandberg
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Anders Ullén
Department of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden
2 shared publications - Bo Lennernäs
Department of Oncology, Sahlgrenska Hospital and Academy, University of Gothenburg, Gothenburg, Sweden
2 shared publications - Lena Sharp
Department of Nursing, Umea University, Umea, Sweden
2 shared publications - Marianne Frostvik Stolt
Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital, 171 76, Solna, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 29 August 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-9
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might benefit from adjuvant therapies. The aim was to examine if cellular immune markers in association with tumor proliferation rate and BRAF mutation status have an impact on prognosis in stage III melanoma. We have used two sets of case series with stage III disease: 23 patients with short survival (≤ 13 months) and 19 patients with long survival (≥ 60 months). Lymph node metastases were analyzed for Ki67, CD8 and FOXP3 protein expression using immunohistochemistry. BRAF mutation status was analyzed in a previous study on the same samples. Low tumor proliferation rate was significantly associated with a better prognosis (p = 0.013). Presence of FOXP3+ T cells was not correlated to adverse clinical outcome. A highly significant trend for a longer survival was found in the presence of an increasing number of markers; CD8+ and FOXP3+ T cells, low tumor proliferation and BRAF wildtype status (p = 0.003). Presence of at least three of these four markers was found to be an independent favorable prognostic factor (OR 19.4, 95% CI 1.9-197, p = 0.012), when adjusting for ulceration and number of lymph node metastases. Proliferation alone remained significant in multivariate analyses (OR 26.1, 95% CI 2.0-344, p = 0.013) but with a wider confidence interval. This panel still remained independent when also adjusting for a previously identified prognostic glycolytic-pigment panel. We have demonstrated that presence of immune cells in association with tumor proliferation and BRAF mutation status may further contribute to identify stage III melanoma patients with high risk of relapse.
- 29 August 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-9
Open AccessPresence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might benefit from adjuvant therapies. The aim was to examine if cellular immune markers in association with tumor proliferation rate and BRAF mutation status have an impact on prognosis in stage III melanoma. We have used two sets of case series with stage III disease: 23 patients with short survival (≤ 13 months) and 19 patients with long survival (≥ 60 months). Lymph node metastases were analyzed for Ki67, CD8 and FOXP3 protein expression using immunohistochemistry. BRAF mutation status was analyzed in a previous study on the same samples. Low tumor proliferation rate was significantly associated with a better prognosis (p = 0.013). Presence of FOXP3+ T cells was not correlated to adverse clinical outcome. A highly significant trend for a longer survival was found in the presence of an increasing number of markers; CD8+ and FOXP3+ T cells, low tumor proliferation and BRAF wildtype status (p = 0.003). Presence of at least three of these four markers was found to be an independent favorable prognostic factor (OR 19.4, 95% CI 1.9-197, p = 0.012), when adjusting for ulceration and number of lymph node metastases. Proliferation alone remained significant in multivariate analyses (OR 26.1, 95% CI 2.0-344, p = 0.013) but with a wider confidence interval. This panel still remained independent when also adjusting for a previously identified prognostic glycolytic-pigment panel. We have demonstrated that presence of immune cells in association with tumor proliferation and BRAF mutation status may further contribute to identify stage III melanoma patients with high risk of relapse.
- 23 July 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 65, 43-51
Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study
- 23 July 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 65, 43-51
Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study
- Open Access
- 1 April 2016
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 2, 6-11
Patients' knowledge and perceived understanding – Associations with consenting to participate in cancer clinical trials
- 1 April 2016
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 2, 6-11
Open AccessPatients' knowledge and perceived understanding – Associations with consenting to participate in cancer clinical trials
- 1 December 2015
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 19 (6) , 724-730
Nurse-led outpatient clinics in oncology care – Patient satisfaction, information and continuity of care
- 1 December 2015
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 19 (6) , 724-730
Nurse-led outpatient clinics in oncology care – Patient satisfaction, information and continuity of care
- 1 April 2015
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 19 (2) , 142-147
Information exchange in oncological inpatient care – Patient satisfaction, participation, and safety
- 1 April 2015
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 19 (2) , 142-147
Information exchange in oncological inpatient care – Patient satisfaction, participation, and safety
- 29 October 2014
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 46 (1) , 381-388
Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities
Effects on long-term health-related quality of life (HRQoL) were evaluated in patients treated for localized prostate cancer by two standard modalities: radical retropubic prostatectomy (RP) and external beam radiotherapy combined with a high-dose-rate brachytherapy boost (HDRBT-EBRT). The HRQoL data were compared with age-adjusted normative data. Men diagnosed with localized prostate cancer and treated with curative intent in Gothenburg, Sweden, 1988-1997 were included. HRQoL was measured in October 2000 using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires, with a response rate of 82% (n=347). No differences in patient characteristics were found between the two treatment groups, except regarding tumor stage and PSA recurrence at the time of the questionnaires. In the RP group, 42% had T1 and 6% had T3-4 tumors; corresponding proportions in the HDRBT-EBRT group were 29% and 13% (p=0.01). PSA recurrence was detected in 44% of RP patients and 9% of HDRBT-EBRT patients. In most domains, mean HRQoL scores were high and similar to the scores for the age-adjusted normative sample. However, patients reported better role and physical function compared to the normal population. We also observed more sleeping disturbances but less pain among patients than in the normal population. The disease-specific questionnaires showed statistically significant higher levels of bowel and urinary problems in the irradiated group than in the RP group, and the absolute difference between the groups was small and had minor clinical significance. We conclude that overall the general quality of life was rated high by the patients irrespective of curative treatment modality and in agreement with age-adjusted normative data. Statistically significant differences in bowel and urinary symptoms were found between the two treatment groups in favor of the RP group, but the clinical significance was small.
- 29 October 2014
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 46 (1) , 381-388
Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities
Effects on long-term health-related quality of life (HRQoL) were evaluated in patients treated for localized prostate cancer by two standard modalities: radical retropubic prostatectomy (RP) and external beam radiotherapy combined with a high-dose-rate brachytherapy boost (HDRBT-EBRT). The HRQoL data were compared with age-adjusted normative data. Men diagnosed with localized prostate cancer and treated with curative intent in Gothenburg, Sweden, 1988-1997 were included. HRQoL was measured in October 2000 using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires, with a response rate of 82% (n=347). No differences in patient characteristics were found between the two treatment groups, except regarding tumor stage and PSA recurrence at the time of the questionnaires. In the RP group, 42% had T1 and 6% had T3-4 tumors; corresponding proportions in the HDRBT-EBRT group were 29% and 13% (p=0.01). PSA recurrence was detected in 44% of RP patients and 9% of HDRBT-EBRT patients. In most domains, mean HRQoL scores were high and similar to the scores for the age-adjusted normative sample. However, patients reported better role and physical function compared to the normal population. We also observed more sleeping disturbances but less pain among patients than in the normal population. The disease-specific questionnaires showed statistically significant higher levels of bowel and urinary problems in the irradiated group than in the RP group, and the absolute difference between the groups was small and had minor clinical significance. We conclude that overall the general quality of life was rated high by the patients irrespective of curative treatment modality and in agreement with age-adjusted normative data. Statistically significant differences in bowel and urinary symptoms were found between the two treatment groups in favor of the RP group, but the clinical significance was small.
- 1 June 2014
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 18 (3) , 305-309
Patients' perception of information after completion of adjuvant radiotherapy for breast cancer
- 1 June 2014
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 18 (3) , 305-309
Patients' perception of information after completion of adjuvant radiotherapy for breast cancer
- Open Access
- 19 November 2013
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 13 (1) , 30
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer
A deregulated energy metabolism is a hallmark of malignant disease that offers possible future targets for treatment. We investigated the prognostic value of the glycolytic enzymes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase type M2 (PKM2), mitochondrial β-F1-ATPase (ATP5B) and the bioenergetic cellular (BEC) index in advanced ovarian cancer.
- 19 November 2013
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 13 (1) , 30
Open AccessMetabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer
A deregulated energy metabolism is a hallmark of malignant disease that offers possible future targets for treatment. We investigated the prognostic value of the glycolytic enzymes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase type M2 (PKM2), mitochondrial β-F1-ATPase (ATP5B) and the bioenergetic cellular (BEC) index in advanced ovarian cancer.